Commentary on “Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer”
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2025-013210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Nour Kotaich und 1 weiteren Autor:innen. Beteiligte Einrichtung: UR7509, Université de Reims Champagne-Ardenne, Reims, Grand Est, France. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Fatty Acids, B7 Antigens, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by limited treatment options and poor prognosis. Immune checkpoint blockade, particularly via programmed cell death protein-1/programmed death-ligand 1 inhibition, has improved outcomes in selected patients with TNBC; however, resistance remains a major barrier. Recent studies have identified B7-H3 (CD276) as a key immune-suppressive molecule overexpressed in TNBC, correlating with poor prognosis and immune exclusion. Jiang et al demonstrate that B7-H3 inhibition triggers a compensatory metabolic adaptation in TNBC cells, marked by upregulation of fatty acid synthesis and β-oxidation, particularly via the AKT-SREBP1-FASN signaling axis. This metabolic reprogramming promotes survival and immune evasion, limiting the efficacy of B7-H3-targeted therapies. Dual inhibition of B7-H3 and fatty acid synthase synergistically enhances tumor cell apoptosis, suppresses proliferation and migration, and promotes CD8 + T-cell infiltration in vitro and in vivo. These findings reveal a novel immune-metabolic resistance mechanism in TNBC and provide a compelling rationale for combinatorial strategies targeting both immune checkpoints and metabolic pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UR7509, Université de Reims Champagne-Ardenne, Reims, Grand Est, France.
- UR7509, Université de Reims Champagne-Ardenne, Reims, Grand Est, France stephane.potteaux@univ-reims.fr.
- Département de Recherche, Institut Godinot, Reims, France.
- Inserm, Délégation régionale Paris Île-de-France Centre Nord, Paris, France.
Zitieren
APA
Kotaich, N., & Potteaux, S. (2026). Commentary on “Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer”. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013210
Vancouver
Kotaich N, Potteaux S. Commentary on “Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer”. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-013210
BibTeX
@article{Kotaich2026,
author = {Kotaich, Nour and Potteaux, Stéphane},
title = {Commentary on “Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer”},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2025-013210}
}
EUVIMED